fbpx
weight-loss-clinic-cv

Dr Hendricks

ED J. HENDRICKS, M.D.

 

Education

B.A. Rice University, Houston, Texas
M.D. College of Physicians & Surgeons, Columbia University, New York City

Postgraduate Training

Internal Medicine, University of Texas Southwestern Medical School & Parkland Hospital, Dallas, Texas
Clinical and Anatomical Pathology, University of Minnesota Medical School & Hospital, Minneapolis, Minnesota

Honors

Full Tuition Scholarship, Rice University
Phi Beta Kappa, Rice University
Dean’s Scholarship, College of Physicians & Surgeons, Columbia University
National Institutes of Health Fellowship, University of Minnesota
Bariatric Physician of the Year, 2009, American Society of Bariatric Physicians
Fellow, American Society of Bariatric Physicians, 2010
Vernon B. Astler Award, American Society of Bariatric Physicians, 2011
Raymond E. Dietz Award, American Society of Bariatric Physicians, 2013
Distinguished Achievement Award, Obesity Medicine Association, 2017

Board Certifications

American Board of Obesity Medicine, (formerly American Board Bariatric Medicine)
American Board of Pathology, Clinical & Anatomic Pathology

Medical Licensure

California

Experience

Pathologist, U.S. Air Force Hospital, Anchorage, Alaska, 1966-1969
Associate Pathologist, St. Joseph Hospital, Houston, Texas, 1969-1972
Chief Pathologist, Fresno Community Hospital, Fresno, California, 1972-1986
Private Pathology Practice, Fresno, California, 1986-1988
Associate Pathologist, Mercy San Juan & Mercy Folsom Hospitals, Carmichael & Folsom, California, 1988-1989
Center for Weight Management, Roseville & Sacramento California, 1989 – Present

Of Note

Master Fellow, Obesity Medicine Association (MFOMA), 2017
Ex-Officio Trustee, Obesity Treatment Foundation, 2016-
President, Board of Trustees, Obesity Treatment Foundation, 2013-2016
FDA Endocrine and Metabolic Drug Advisory Committee, 2010-2015
Ex-Officio Trustee, American Society of Bariatric Physicians, 2011- 2013
Fellow, American Society of Bariatric Physicians 2010
Trustee, Board of Directors, American Society of Bariatric Physicians, 2008 – 2010
Secretary-Treasurer, American Board of Bariatric Medicine, 2002-2007
Trustee, Board of Directors, American Board of Bariatric Medicine, 2000 – 2007
President, California Society of Pathologists, 1986
Trustee, Board of Directors, California Society of Pathologists, 1980 – 1986

Memberships

Obesity Medicine Association (OMA, aka American Society of Bariatric Physicians ASBP)
The Obesity Society (TOS, aka North American Society for the Study of Obesity)
Member, Nutrition and Metabolism Society
Fellow, College of American Pathologists (inactive)
Fellow, American Society of Clinical Pathologists (inactive)
California Society of Pathologists (inactive)

Hospital Medical Staff Memberships (all past)

Roseville Hospital, Roseville
Mercy Folsom Hospital, Folsom
Mercy San Juan Hospital, Carmichael
Tulare County Hospital, Visalia
Fresno Community Hospital, Fresno
Clovis Community Hospital, Clovis
Veterans Administration Hospital Consultant, Fresno
St. Joseph Hospital, Houston
U.S.A.F Hospital Elmendorf, Anchorage

Continuing Medical Education (recent only)

Weight of the Nation, Jump Start/Low Carb USA, San Francisco 2018
Obesity Medicine Association, Annual Seminar, Washington, DC 2018
Obesity Medicine Association, Spring Course, San Diego 2018
Obesity Society (TOS), Obesity Week, Washington, DC, 2017
Obesity Medicine Association Annual Seminar, San Antonio, 2017
Obesity Medicine Association, Spring Course, Seattle 2017
Obesity Medicine Association, Spring Course, San Francisco 2016
Nutrition and Metabolism Society Annual Meeting, San Francisco 2016
Obesity Medicine Association Annual Seminar, Washington, DC, 2015
Obesity Society, Obesity Week, Los Angeles, 2015
American Society of Bariatric Physicians, Spring Course, Denver 2015
Nutrition and Metabolism Society Annual Meeting, Denver 2015
American Society of Bariatric Physicians, Annual Seminar, Austin 2014
iNova National Obesity Forum. iNova Pharmaceuticals: Adelaide, Australia, 2014
American Society of Bariatric Physicians, Spring Course, Philadelphia 2014
Nutrition and Metabolism Society Annual Meeting, Philadelphia 2014
Obesity Society Annual Scientific Meeting, Atlanta, 2013
American Society of Bariatric Physicians, Annual Seminar, Phoenix, 2013
European Congress on Obesity, Liverpool, U.K., 2013
American Society of Bariatric Physicians, Certification Review Course, San Diego, 2013
American Society of Bariatric Physicians, Spring Seminar, San Diego, 2013
Nutrition and Metabolism Society Annual Meeting, San Diego, 2013
Obesity Society Annual Scientific Meeting, San Antonio, 2012
American Society of Bariatric Physicians Annual Seminar, Orlando, 2012
American Society of Bariatric Physicians, Spring Seminar, Denver, 2012
Nutrition and Metabolism Society Annual Meeting, Denver, 2012
Obesity Society Annual Scientific Meeting, Orlando, 2011
American Society of Bariatric Physicians Annual Seminar, Las Vegas, 2011
Obesity Society Annual Scientific Meeting, San Diego, CA 2010
American Society of Bariatric Physicians Annual Seminar, New Orleans, 2010
Obesity Society Annual Scientific Meeting, Washington, DC, 2009
American Society of Bariatric Physicians Annual Seminar, Costa Mesa, 2009
American Society of Bariatric Physicians and Metabolism Society, Charleston, 2009
American Society of Bariatric Physicians Annual Seminar, Tampa, 2008
Obesity Society (NAASO), Annual Scientific Meeting, Phoenix, 2008
American Society of Bariatric Physicians Spring Meeting, Phoenix, 2008

Papers Published or Presented

1. Hendricks EJ. Off-label drugs for weight management. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2017;10:223-234.
2. Miguelgorry PL, Hendricks EJ. Pharmacotherapy for Obesity and Changes in Eating Behavior: a Patient and Physician’s Perspective. Adv Ther. 2016;33(7):1262-1266.
3. Hendricks EJ. The Role of Duromine in Obesity Management – The US experience. New Zealand General Practice Conference & Medical Exhibition; June 10, 2016; Rotorua.
4. Hendricks EJ. Pharmacotherapy, Chapter 8. In: Steelman GM, Westman EC, eds. Obesity, Evaluation and Treatment Essentials. Second ed. Boca Raton, Florida, USA: CRC Press; 2016:137-167.
5. Schmidt SL, Bryman D, Greenway FL, Hendricks EJ. How Physician Obesity Medicine Specialists Treated Obesity before 2012 New Drug Approvals. Obes Surg. 2015;25(1):186-190.
6. Hendricks EJ, Rothman RB, Bryman DA, Schmidt SL. Association of subarachnoid hemorrhage and phentermine usage: Coincidence, not causation. J Am Pharm Assoc (2003). 2015;55(2):122, 124.
7. Hendricks EJ, Rothman RB. The Case of Posterior Reversible Encephalopathy With Intracranial Hemorrhage was Likely due to Uncontrolled Hypertension, and was Unrelated and Coincidental to Long-term Phentermine Use. Neurologist. 2015;19(4):118-119.
8. Hendricks EJ, Greenway F, Schmidt SL, Hendricks MJ, Istratiy Y. Clinical Experience with the Eating Behavior Questionnaire. 65th Annual Symposium of the American Society of Bariatric Physicians; 2015; Washington, D.C. .
9. Hendricks EJ, Srisurapanont M, Schmidt SL, et al. Addiction potential of phentermine prescribed during long-term treatment of obesity. International Journal of Obesity. 2014;38(2):292-298.
10. Hendricks EJ, Schmidt SL, Greenway FL, Istratiy Y, Hendricks MJ. Eating Behavior Questionnaire: Treatment-induced Changes in EBQ Scores. Overcoming Obesity Annual Symposium; September 12, 2014; Austin, Texas.
11. Hendricks EJ, Greenway F, Schmidt SL, Hendricks MJ, Istratiy Y. The Eating Behavior Questionnaire: A novel clinical examination. Obesity Course: Diagnosis to Treatment; March 15, 2014; Philadelphia, PA.
12. Hendricks EJ. Effective medical treatment for obesity In: iNova, ed. iNova Dinner Talks. Adelaide, Perth, Melbourne, Brisbane, Australia: iNova; 2014.
13. Hendricks EJ. The future of weight management. iNova National Obesity Forum; August 10, 2014; Adelaide, Australia.
14. Hendricks EJ. Phentermine – your key questions answered. iNova National Obesity Forum; August 9, 2014; Adelaide, Australia.
15. Hendricks EJ. Forming long-term partnerships to optimise weight management. iNova National Obesity Forum; August 9, 2014; Adelaide, Australia.
16. Seger J, Horn DB, Westman E, et al. ASBP Obesity Algorithm: Adult Adiposity Evaluation & Treatment 2013. 2013; http://asbp.org/obesityalgorithm.html. Accessed October 14, 2013.
17. Schmidt SL, Bryman D, Hendricks EJ, Greenway F. Pharmacotherapy Prescribing Practices Survey: ASBP 2012. Denver: American Society of Bariatric Physicians; 2013.
18. Schmidt SL, Bryman D, Hendricks EJ. Changes in Prescribing Practices of Obesity Medicine Specialists in the United States 2008-2012. ECO 2013; 2013; Liverpool, UK.
19. Hendricks EJ, Greenway F, Srisurapanont M, et al. Long-term Phentermine Pharmacotherapy: An Investigation for Amphetamine-like Phentermine Addiction, Abuse, Cravings, or Withdrawal. ECO 2013; 2013; Liverpool, UK.
20. Hendricks EJ. Copyright: Eating Behavior Questionnaire. Registration Number: TXu 1-894-444 ed: United States Copyright Office; 2013.
21. Hendricks EJ. Pharmacotherapy. Obesity Medicine Certification Review Course; 2013; San Diego.
22. Bryman D, Hendricks EJ, Schmidt SL. Incidence of Addiction and Abuse due to Phentermine, Diethylpropion, and Phendimetrazine in the United States2013, Unpublished manuscript.
23. Hendricks EJ. Trends in U.S.A. Obesity Treatment. Panbesy Asian Conference Tour; 2012, March 9; Chinese University of Hong Kong Medical School, .
24. Hendricks EJ. Treatment of Obesity in the post-Sibutramine Era. What Are the Options? Panbesy Asia Conference Tour; 2012, March 7&8; Seoul, Korea.
25. Schmidt SL, Hendricks EJ. The Use of Pharmacotherapy for Obesity Treatment in the United States. 62nd Annual Obesity and Related Disorders Symposium of the American Society of Bariatric Physicians; October 26, 2012; Orlando.
26. Hendricks EJ, Greenway F, Srisurapanont M, Hendricks MJ, De Marco D. Long-term Phentermine Pharmacotherapy: An Investigation for Symptoms of Amphetamine-like Phentermine Dependence, Cravings, or Withdrawal. 62nd Annual Obesity and Related Disorders Symposium of the American Society of Bariatric Physicians; 2012; Orlando.
27. Hendricks EJ, Greenway F, Srisurapanont M, De Marco D, Hendricks MJ. Long-term Phentermine Pharmacotherapy: An Investigation for Symptoms of Dependence, Cravings, or Withdrawal: a Prospective trial. 2012. Located at: NCT01402674, Sacramento.
28. Hendricks EJ. Letter by hendricks regarding article, “obesity and cardiovascular disease”. Circulation. 2012;126(12):e191; author reply e192.
29. Hendricks EJ. Using Phentermine, Topiramate, & Qsymia. 62nd Annual Obesity and Related Disorders Symposium of the American Society of Bariatric Physicians; 2012; Orlando.
30. Hendricks EJ. Two Addiction Medicine Studies in Patients treated with phentermine long-term 62nd Annual Obesity and Related Conditions Symposium of the American Society of Bariatric Physicians; October 26, 2012, 2012; Orlando.
31. Hendricks EJ. Cardiovascular Outcomes Trials for New Obesity Drugs. 62nd Annual Obesity and Related Conditions Symposium of the American Society Bariatric Physicians October 26, 2012; Orlando.
32. Hendricks EJ. Treatment of Obesity in the post-Sibutramine Era. What are the Options? Panbesy Asia Conference Tour; March 3, 2012; Singapore.
33. Hendricks EJ, Rothman RB. Phentermine therapy for obesity does not elevate blood pressure. Diabetes Obes Metab. 2011;13(10):963-964.
34. Hendricks EJ, Rothman RB. RE: Pulmonary Hypertension Associated with Use of Phentermine? Yonsei Med J. 2011;52(5):869-870.
35. Hendricks EJ, Greenway FL, Westman EC, Gupta AK. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Silver Spring). 2011;19(12):2351-2360.
36. Hendricks EJ, Greenway FL. A Study of Abrupt Phentermine Cessation in Patients in a Weight Management Program. American Journal of Therapeutics. 2011;18(4):292-299.
37. Hendricks EJ. Should the FDA approval process for weight-loss drugs be modified? Am J Health Syst Pharm. 2011;68(21):2094-2095.
38. Hendricks EJ. Rhabdomyolysis and phentermine: Coincidence, not causation. Am J Health Syst Pharm. 2011;68(15):1386-1395.
39. Rothman RB, Hendricks EJ. Phentermine cardiovascular safety II: response to Yosefy Int J Cardiol. 2009 Epub Mar 19. Int J Cardiol. 2010;145(2):391-392.
40. Rothman RB, Hendricks EJ. Phentermine cardiovascular safety II: response to Yosefy Int J Cardiol. 2009 Epub Mar 19. Int J Cardiol. 2010;145(2):391-392.
41. Rothman RB, Hendricks EJ. Phentermine cardiovascular safety. In response to Yosefy C, Berman M, Beeri R. Cusp tear in bicuspid aortic valve possibly caused by phentermine. International journal of cardiology 2006;106:262-3. Int J Cardiol. 2010;144(2):241-242; author reply 242-243.
42. Rothman RB, Hendricks EJ. Phentermine cardiovascular safety II: Response to Yosefy Int J Cardiol. 2009 Epub Mar 19. Int J Cardiol. 2010;145(2):391-392.
43. Hendricks EJ, Greenway F, Westman E, Gupta AK. Phentermine pharmacotherapy for Weight Management in Overweight to Morbidly Obese Subjects does not alter seated resting office blood pressure 475P Obesity. 2010;18, S2(Supplement 2):S151.
44. Hendricks EJ. Pharmcotherapy, Chapter 8. In: Steelman GM, Westman E, eds. Obesity: Evaluation and Treatment Essentials. First ed. New York, New York: Informa Healthcare; 2010:81-99.
45. Rothman RB, Hendricks EJ. Phentermine Cardiovascular Safety. American Journal of Emergency Medicine. 2009;27(8):1010-1013.
46. Hendricks EJ, Rothman RB, Greenway FL. How physician obesity specialists use drugs to treat obesity. Obesity (Silver Spring). 2009;17(9):1730-1735.
47. Hendricks EJ, Greenway FL. Symptoms Observed after Abrupt Phentermine Cessation 223-P. Obesity. 2009;17(Suppl 2):S111.
48. Hendricks EJ, Greenway FL. Symptoms Observed after Abrupt Phentermine Cessation. 27th Annual Scientific Meeting; October 25, 2009; Washington, D.C.
49. Hendricks EJ. Is Phentermine Addicting? 59th Annual Obesity & Associated Conditions Symposium; October 10, 2009, 2009; Costa Mesa.
50. Hendricks EJ, Westman EC. Phentermine Therapy in Obesity Treatment: Effect on Blood Pressure 582P. Obesity. 2008;16, Supplement 1(October):S216.
51. Hendricks EJ, Greenway FL, Westman EC, et al. A Survey of Prescribing Practices of Medical Bariatricians. Obesity. 2008;16(October, Supplement 1):S292-293.
52. Hendricks EJ. Adverse Reactions to Phentermine, Evidence versus Conjecture. 58th Annual Obesity & Associated Conditions Symposium; 2008; Tampa, FL.
53. Hendricks EJ. ASBP Membership Survey of Prescribing Practices. Survey presented at 58th Annual Obesity & Associated Conditions Symposium; May 2008; Tampa, Florida.
54. Hendricks EJ. “Pharmacotherapy of Obesity”. Annual Review Course, American Board of Bariatric Medicine; May 1, 2007; Nashville, TN.
55. Hendricks EJ. “Indications for Phentermine Use in Treating Obesity: Re-examination of Current Guidelines”. Eastern Regional Obesity Course, American Society of Bariatric Physicians; May 4, 2007; Nashville, TN.
56. Hendricks EJ. “Using the Web to Stay Current with Obesity Treatment and Research”. 56th Annual Obesity & Associated Conditions Symposium 2006; San Diego, CA.
57. Hendricks EJ. “Pharmacotherapy of Obesity”. Annual Review Course, American Board of Bariatric Medicine; May 10, 2006; Lexington, KY.
58. Hendricks EJ. Weight Control Pharmacology in Bariatric Surgical Practice. Bariatric Times. Vol 32006:1,16-19.
59. Hendricks EJ, Bryman, D. A., Roldan, E. O. Insurance Panel Debate: Pros and Cons. 55th Annual Obesity & Associated Conditions Symposium; October 31, 2005, 2005; Las Vegas.
60. Hendricks EJ. “New Obesity Drugs: Current Status Report”. Eastern Regional Obesity Course, American Society of Bariatric Physicians; May 12, 2005; Atlanta, GA.
61. Hendricks EJ. “Pharmacotherapy of Obesity”. Annual Review Course, American Board of Bariatric Medicine; May 11, 2005; Atlanta, GA.
62. Hendricks EJ. “Pharmacotherapy of Obesity”. Annual Review Course, American Board of Bariatric Medicine; May 5, 2004, 2004; Scottsdale, AZ.
63. Hendricks EJ. “Pathophysiology of Obesity”. Annual Review Course, American Board of Bariatric Medicine; May 4, 2004; Scottsdale, AZ.
64. Hendricks EJ. “Pharmacotherapy of Obesity”. Annual Review Course, American Board Bariatric Medicine; May 7, 2003; Las Vegas, NV.
65. Hendricks EJ. “New Bariatric Drugs”. Western Regional Obesity Course, American Society Bariatric Physicians; May 10, 2003; Las Vegas, NV
66. Hendricks EJ. “Pharmacotherapy of Obesity”. Annual Review Course, American Board Bariatric Medicine; May 16, 2002; Denver, CO.
67. Hendricks EJ. “Pathophysiology of Obesity”. Paper presented at: Basic Bariatric Course, American Society Bariatric Physicians; September 17, 2002; Boston, MA.
68. Hendricks EJ. New Drugs for Obesity: Drugs in Phase 2 Clinical Trials. American Journal Bariatric Medicine. 2002;17(2):17-.
69. Hendricks EJ. New Drugs for Obesity: Drugs in Phase 1 Clinical Trials. American Journal Bariatric Medicine. 2002;17(2):16-.
70. Hendricks EJ. “Pharmacotherapy of Obesity”. Annual Review Course, American Board Bariatric Medicine; April 26, 2001; Atlanta, GA.
71. Hendricks EJ. “New Drugs on the Horizon”. Paper presented at: 51st Annual Obesity & Associated Conditions Symposium, American Society Bariatric Physicians; October 27, 2001; San Diego, CA.
72. Hendricks EJ. New Drugs for Obesity: Drugs in Phase 3 Clinical Trials. American Journal Bariatric Medicine. 2001;16(3):15-.
73. Hendricks EJ. Laboratory computers: tools for increased productivity. Clin Lab Med. 1985;5(4):709-723.
74. Chen KT, Hendricks EJ. Malakoplakia of the female genital tract. Obstet Gynecol. 1985;65(3 Suppl):84S-87S.
75. Hendricks EJ, Langhofer LA. A community hospital laboratory computer system: an eight-year longitudinal study of economic impact. Am J Clin Pathol. 1982;77(3):297-304.
76. Chen KT, Hendricks EJ, Freeburg B. Benign glandular inclusion of the peritoneum associated with leiomyomatosis peritonealis disseminata. Diagn Gynecol Obstet. 1982;4(1):41-44.
77. Hendricks EJ. “The Computerized Laboratory of the Future”. Paper presented at: Symposium on Clinical Decision Making and Laboratory Use, Riyadh-Al-Karj Hospital; January 5, 1981; Riyadh, Saudi Arabia.
78. Chen KT, Hoffman KD, Hendricks EJ. Angiosarcoma following therapeutic irradiation. Cancer. 1979;44(6):2044-2048.
79. Hendricks EJ. “Mechanisms of Subspecialty Training: Where -University or Private Hospital”. Paper presented at: Symposium on the Future of Graduate Medical Education in Pathology, American Society Clinical Pathologists; November, 1976; Monterey, CA.
80. Hendricks EJ. “How Should the Pathologist be Trained to Fulfill His Clinical Role?”. Paper presented at: Symposium on the Future of Graduate Medical Education in Pathology, American Society Clinical Pathologists; November, 1976; Monterey, CA.
81. Simon RG, Langhofer LA, Jr., Hendricks EJ. Australia Antigen Content of Commercial Quality-Control Sera. Clin Chem. 1973;19(2):221-222.
82. Hendricks EJ. “Use of Amniotic Fluid Analysis in Prenatal Management of Rh Disease”. Paper presented at: Annual Meeting, Texas Medical Association; April 1, 1972; Houston, Texas.
83. Hendricks EJ. Quality control in transition; use of computers in the laboratory. Postgrad Med. 1968;44(5):67-69.
84. Hendricks EJ. Methods of blood glucose determination. Postgrad Med. 1967;42(1):A46 passim.
85. Hendricks E. Laboratory Tests of Anterior Pituitary Function. Postgrad Med. 1965;37:A44-52.

Disclosures

I have served as a speaker for:
Eurodrug Laboratories B.V., The Hauge, Netherlands.
Akrimax Pharmaceuticals, Cranford, New Jersey.
Vivus Pharmaceuticals, Mountain View, California
iNova Pharmaceuticals, Sydney, Australia
Radiant Health, Auckland, New Zealand
Novo Nordisk, Princeton, New Jersey

I have consulted for:
CTS Group, Tel-Aviv, Israel
Citius Pharmaceuticals, Maynard, Massachusetts.
Rodman & Renshaw, LLC, New York, New York
GLG Research, Austin Texas
Credit Suisse, New York, New York
WallachBeth Capital LLC, New York, New York

I have served as expert witness for:
John H. Cotton & Associates, Las Vegas, Nevada.
Oliver Maner, LLP, Savannah, Georgia.
Creed C. Black, Esq., Philadelphia, Pennsylvania
Naulty, Scaricamazza & McDevitt, LLC, Philadelphia, Pennsylvania.
Kane, Pugh, Knoell, Troy & Kramer, LLP, Norristown, Pennsylvania.
Gregory Unatin, Esq., Pittsburg, Pennsylvania
Theresa Dillard, Esq., San Francisco, California
Smith & Taylor, Henderson, Las Vegas, Nevada.
Silverman, Decaria & Kattleman, Reno, Nevada.
Steven Hillyard, Inc., San Francisco, California
Saber Attorneys at Law, Florham Park, New Jersey
Allison Kennickell, Esq., Savannah, Georgia
Richard A. Jaffe, Esq., Sacramento, California
Janet I. Mittenfelner, Esq., Kansas City, Missouri
Ryals, Donaldson & Agricola, P.C., Montgomery, Alabama
Melanie L. Balestra, NP, Esq., Irvine, California
Tina I. Mangarpan, Esq., of Ford, Walker, Haggerty & Behar, LLP, Long Beach, California
Vernon L. Krueger, Esq,, of Krueger Law Group, LLP, Dallas Texas.

I have received funding for research from:
Obesity Medicine Association (formerly American Society of Bariatric Physicians)
Obesity Treatment Foundation
Center for Weight Management

Schedule A Consultation

Three months from today, you'll be glad you made the decision to start!

  • Hendricks Shop

    Our clinical and nutrition experts have already vetted products for maximum effectiveness and taste.
    Go to Shop
  • Patient Stories

    For over twenty years, we have served thousands of patients. Let some of your peers share with you their stories of triumph and lives transformed.
    Read more
  • Roseville Office

    Closed for lunch every day between 1:00-2:00 pm.

    • Monday
      9:00 am - 4:30pm
    • Tuesday
      9:00 am - 5:00pm
    • Wednesday
      9:00 am - 5:00pm
    • Thursday
      9:00 am - 5:00pm
    • Friday
      9:00 am - 5:00pm
    • Saturday
      9:00 am - 4:30pm
  • Sacramento Office

    Closed for lunch between
    1:00-2:00pm.

    • Tuesday
      9:00 am - 5:00pm
    • Thursday
      9:00 am - 5:00pm